Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Akt Cys-310-targeted inhibition by hydroxylated benzene derivatives is tightly linked to their immunosuppressive effects.

Authors
  • Lee, Ji Yeon
  • Lee, Yong Gyu
  • Lee, Jaehwi
  • Yang, Keum-Jin
  • Kim, Ae Ra
  • Kim, Joo Young
  • Won, Moo-Ho
  • Park, Jongsun
  • Yoo, Byong Chul
  • Kim, Sanghee
  • Cho, Won-Jea
  • Cho, Jae Youl
Type
Published Article
Journal
Journal of Biological Chemistry
Publisher
American Society for Biochemistry and Molecular Biology
Publication Date
Mar 26, 2010
Volume
285
Issue
13
Pages
9932–9948
Identifiers
DOI: 10.1074/jbc.M109.074872
PMID: 20054000
Source
Medline
License
Unknown

Abstract

The hydroxylated benzene metabolite hydroquinone (HQ) is mainly generated from benzene, an important industrial chemical, and is also a common dietary component. Although numerous reports have addressed the tumorigenesis-inducing effects of HQ, few papers have explored its molecular regulatory mechanism in immunological responses. In this study we characterized Akt (protein kinase B)-targeted regulation by HQ and its derivatives, in suppressing inflammatory responses using cellular, molecular, biochemical, and immunopharmacological approaches. HQ down-regulated inflammatory responses such as NO production, surface levels of pattern recognition receptors, and cytokine gene expression with IC(50) values that ranged from 5 to 10 microm. HQ inhibition was mediated by blocking NF-kappaB activation via suppression of its translocation pathway, which is composed of Akt, I kappaB alpha kinase beta, and I kappaB alpha. Of the targets in this pathway, HQ directly targeted and bound to the sulfhydryl group of Cys-310 of Akt and sequentially interrupted the phosphorylation of both Thr-308 and Ser-473 by mediation of beta-mercaptoethanol, according to the liquid chromatography/mass spectroscopy analysis of the interaction of HQ with an Akt-derived peptide. Therefore, our data suggest that Akt and its target site Cys-310 can be considered as a prime molecular target of HQ-mediated immunosuppression and for novel anti-Akt-targeted immunosuppressive drugs.

Report this publication

Statistics

Seen <100 times